Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009; 262. Piotrowicz E, Baranowski R, Bilinska M, Stepnowska M, Piotrowska M, Wojcik A et al. A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence. European Journal of Heart Failure. 2010; 263. Piotrowicz E, Stepnowska M, Leszczynska-Iwanicka K, Piotrowska D, Kowalska M, Tylka J et al. Quality of life in heart failure patients undergoing home-based telerehabilitation versus outpatient rehabilitation a randomized controlled study. European Journal of Cardiovascular 264. Pitt B, Gheorghiade M, Zannad F, Anderson JL, Van V, Parkhomenko A et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction less-than or equal to 30%. European Journal of Heart Failure. 2006; 8(3):295-301 265. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine. 2014; 266. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine. 2003; 348(14):1309-1321 267. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology. 2005; 46(3):425-431 268. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. 